Richard Lowenthal
Co-Founder, President and CEO
CEO
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | ARS Pharmaceuticals, Inc. (SPRY) | M.S., MSEL President and Chief Executive Officer | $651,000 | $7,174,995 |
| 2023 | ARS Pharmaceuticals, Inc. (SPRY) | M.S., MSEL President and Chief Executive Officer | $620,000 | $10,039,096 |
| 2022 | ARS Pharmaceuticals, Inc. (SPRY) | M.S., MSEL President and Chief Executive Officer | $74,630 | $476,343 |
Executive changes
- 2026-07-15
- 2026-07-06
-
Appointed President, Chief Executive Officer and Class II Director at ARS Pharmaceuticals, Inc. (SPRY)2022-11-08
Earnings-call appearances
-
ARS Pharmaceuticals, Inc. Q4 FY2025 Earnings Call2026-03-09
ARS Pharmaceuticals, Inc. (SPRY)
-
ARS Pharmaceuticals, Inc. Q3 FY2025 Earnings Call2025-11-10
ARS Pharmaceuticals, Inc. (SPRY)
-
ARS Pharmaceuticals, Inc. Q2 FY2025 Earnings Call2025-08-13
ARS Pharmaceuticals, Inc. (SPRY)
-
ARS Pharmaceuticals, Inc. Q1 FY2025 Earnings Call2025-05-14
ARS Pharmaceuticals, Inc. (SPRY)
-
ARS Pharmaceuticals, Inc. Q4 FY2024 Earnings Call2025-03-20
ARS Pharmaceuticals, Inc. (SPRY)
-
ARS Pharmaceuticals, Inc. Q3 FY2024 Earnings Call2024-11-13
ARS Pharmaceuticals, Inc. (SPRY)